

Irwin D Bernstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7561613/publications.pdf>

Version: 2024-02-01

47
papers

5,759
citations

172457

29
h-index

243625

44
g-index

49
all docs

49
docs citations

49
times ranked

5384
citing authors

#	ARTICLE	IF	CITATIONS
1	Engineering a niche supporting hematopoietic stem cell development using integrated single-cell transcriptomics. <i>Nature Communications</i> , 2022, 13, 1584.	12.8	23
2	Notch blockade overcomes endothelial cell-mediated resistance of FLT3/ITD-positive AML progenitors to AC220 treatment. <i>Leukemia</i> , 2021, 35, 601-605.	7.2	3
3	Inaccessible LCG Promoters Act as Safeguards to Restrict T Cell Development to Appropriate Notch Signaling Environments. <i>Stem Cell Reports</i> , 2021, 16, 717-726.	4.8	0
4	Multipotent progenitors and hematopoietic stem cells arise independently from hemogenic endothelium in the mouse embryo. <i>Cell Reports</i> , 2021, 36, 109675.	6.4	50
5	Maturation of hematopoietic stem cells from prehematopoietic stem cells is accompanied by up-regulation of PD-L1. <i>Journal of Experimental Medicine</i> , 2018, 215, 645-659.	8.5	19
6	M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion. <i>Blood Advances</i> , 2018, 2, 859-870.	5.2	45
7	NOTCH signaling specifies arterial-type definitive hemogenic endothelium from human pluripotent stem cells. <i>Nature Communications</i> , 2018, 9, 1828.	12.8	97
8	Clonal Analysis of Embryonic Hematopoietic Stem Cell Precursors Using Single Cell Index Sorting Combined with Endothelial Cell Niche Co-culture. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	6
9	A Common Origin for B-1a and B-2 Lymphocytes in Clonal Pre- Hematopoietic Stem Cells. <i>Stem Cell Reports</i> , 2017, 8, 1563-1572.	4.8	41
10	Murine hemogenic endothelial precursors display heterogeneous hematopoietic potential ex vivo. <i>Experimental Hematology</i> , 2017, 51, 25-35.e6.	0.4	16
11	Generating high-purity cardiac and endothelial derivatives from patterned mesoderm using human pluripotent stem cells. <i>Nature Protocols</i> , 2017, 12, 15-31.	12.0	158
12	Gemtuzumab ozogamicin for acute myeloid leukemia. <i>Blood</i> , 2017, 130, 2373-2376.	1.4	130
13	CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2017, 35, 2674-2682.	1.6	120
14	Engineered Murine HSCs Reconstitute Multi-lineage Hematopoiesis and Adaptive Immunity. <i>Cell Reports</i> , 2016, 17, 3178-3192.	6.4	25
15	Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial. <i>Lancet Haematology</i> , 2016, 3, e330-e339.	4.6	26
16	CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2016, 34, 747-755.	1.6	116
17	The Role of Notch in Vascular Endothelial Cell-Mediated Protection of AML Precursors from Targeted Therapy. <i>Blood</i> , 2016, 128, 2750-2750.	1.4	0
18	Endothelium and NOTCH specify and amplify aorta-gonad-mesonephros-derived hematopoietic stem cells. <i>Journal of Clinical Investigation</i> , 2015, 125, 2032-2045.	8.2	74

#	ARTICLE	IF	CITATIONS
19	Inhibition of β -catenin signaling respecifies anterior-like endothelium into beating human cardiomyocytes. <i>Development (Cambridge)</i> , 2015, 142, 3198-209.	2.5	64
20	Angiopoietin-like proteins stimulate HSPC development through interaction with notch receptor signaling. <i>ELife</i> , 2015, 4, .	6.0	30
21	Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. <i>Blood</i> , 2012, 119, 6198-6208.	1.4	273
22	Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. <i>Blood</i> , 2012, 119, 3705-3711.	1.4	91
23	Notch2 governs the rate of generation of mouse long- and short-term repopulating stem cells. <i>Journal of Clinical Investigation</i> , 2011, 121, 1207-1216.	8.2	113
24	Endothelial Cells Are Essential for the Self-Renewal and Repopulation of Notch-Dependent Hematopoietic Stem Cells. <i>Cell Stem Cell</i> , 2010, 6, 251-264.	11.1	582
25	Clinical Strategies to Enhance Posttransplant Immune Reconstitution. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 94-99.	2.0	17
26	CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. <i>Blood</i> , 2007, 109, 4168-4170.	1.4	176
27	FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. <i>Blood</i> , 2006, 108, 2764-2769.	1.4	63
28	Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. <i>Blood</i> , 2005, 106, 2693-2699.	1.4	257
29	Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. <i>Cancer</i> , 2005, 104, 1442-1452.	4.1	429
30	Density of the Notch ligand Delta1 determines generation of B and T cell precursors from hematopoietic stem cells. <i>Journal of Experimental Medicine</i> , 2005, 201, 1361-1366.	8.5	116
31	Culture of CD34+ Umbilical Cord Blood Progenitors with Notch Ligand Results in Enhanced and More Rapid Human Engraftment in a Preclinical NOD/SCID Mouse Model. <i>Blood</i> , 2005, 106, 190-190.	1.4	3
32	The Interaction of the Wnt and Notch Pathways Modulates NK vs. T Cell Commitment. <i>Blood</i> , 2005, 106, 765-765.	1.4	1
33	Combined effects of Notch signaling and cytokines induce a multiple log increase in precursors with lymphoid and myeloid reconstituting ability. <i>Blood</i> , 2003, 101, 1784-1789.	1.4	244
34	CD33 as a Target for Selective Ablation of Acute Myeloid Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2002, 2, S9-S11.	2.1	37
35	Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody-Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia. <i>Bioconjugate Chemistry</i> , 2002, 13, 47-58.	3.6	506
36	An Anti-CD33 Antibody-Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia. Choice of Linker. <i>Bioconjugate Chemistry</i> , 2002, 13, 40-46.	3.6	209

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse. <i>Journal of Clinical Oncology</i> , 2001, 19, 3244-3254.	1.6	837
38	Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. <i>Blood</i> , 2001, 97, 3197-3204.	1.4	314
39	A phase I/II trial of iodine-131-anti-CD20 (tositumomab), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000, 96, 2934-2942.	1.4	173
40	Regulation of colony forming cell generation by flt-3 ligand. <i>British Journal of Haematology</i> , 1996, 94, 17-22.	2.5	18
41	Post therapy imaging in high dose I-131 radioimmunotherapy patients. <i>Medical Physics</i> , 1994, 21, 1157-1162.	3.0	13
42	GATA-1 is expressed in acute erythroblastic leukaemia. <i>British Journal of Haematology</i> , 1994, 86, 410-412.	2.5	10
43	THE USE OF RADIOLABELED ANTI-CD33 ANTIBODY TO AUGMENT MARROW IRRADIATION PRIOR TO MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA. <i>Transplantation</i> , 1992, 54, 829-833.	1.0	153
44	Effect of Interleukin-2 on Biodistribution of Monoclonal Antibody in Tumor and Normal Tissues in Mice Bearing SL-2 Thymoma. <i>Journal of the National Cancer Institute</i> , 1992, 84, 109-113.	6.3	13
45	Prospects for monoclonal antibody therapy of leukemia and lymphoma. <i>Cancer</i> , 1986, 58, 584-589.	4.1	15
46	Food aversions in children receiving chemotherapy for cancer. <i>Cancer</i> , 1982, 50, 2961-2963.	4.1	53
47	Antibody-targeted therapy. , 0, , 639-647.		0